187 related articles for article (PubMed ID: 36064686)
21. Effect of statin use on cardiovascular events and all-cause mortality in immune-mediated inflammatory diseases: A systematic review and meta-analysis involving 148,722 participants.
Xie W; Huang H; Xiao S; Yang X; Zhang Z
Pharmacol Res; 2020 Oct; 160():105057. PubMed ID: 32619724
[TBL] [Abstract][Full Text] [Related]
22. Association of the Coexistence of Somnipathy and Diabetes With the Risks of Cardiovascular Disease Events, Stroke, and All-Cause Mortality: A Systematic Review and Meta-analysis.
Yang XH; Zhang BL; Cheng Y; Fu SK; Jin HM
J Am Heart Assoc; 2022 Jul; 11(14):e024783. PubMed ID: 35861844
[TBL] [Abstract][Full Text] [Related]
23. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.
Vrecer M; Turk S; Drinovec J; Mrhar A
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):567-77. PubMed ID: 14692706
[TBL] [Abstract][Full Text] [Related]
24. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
25. Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study.
Cho Y; Jeong Y; Seo DH; Ahn SH; Hong S; Suh YJ; Kim SH
Atherosclerosis; 2021 Jul; 328():92-99. PubMed ID: 34126505
[TBL] [Abstract][Full Text] [Related]
26. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.
Ramos R; Comas-Cufí M; Martí-Lluch R; Balló E; Ponjoan A; Alves-Cabratosa L; Blanch J; Marrugat J; Elosua R; Grau M; Elosua-Bayes M; García-Ortiz L; Garcia-Gil M
BMJ; 2018 Sep; 362():k3359. PubMed ID: 30185425
[TBL] [Abstract][Full Text] [Related]
27. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
28. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews.
Byrne P; Cullinan J; Smith A; Smith SM
BMJ Open; 2019 Apr; 9(4):e023085. PubMed ID: 31015265
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
30. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
[TBL] [Abstract][Full Text] [Related]
31. Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.
Sasso FC; Lascar N; Ascione A; Carbonara O; De Nicola L; Minutolo R; Salvatore T; Rizzo MR; Cirillo P; Paolisso G; Marfella R;
Cardiovasc Diabetol; 2016 Oct; 15(1):147. PubMed ID: 27733159
[TBL] [Abstract][Full Text] [Related]
32. Statins, risk of diabetes, and implications on outcomes in the general population.
Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Chen TJ; Lin SJ; Chiang CE
J Am Coll Cardiol; 2012 Oct; 60(14):1231-8. PubMed ID: 22884288
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis.
Tonelli M; Lloyd A; Clement F; Conly J; Husereau D; Hemmelgarn B; Klarenbach S; McAlister FA; Wiebe N; Manns B;
CMAJ; 2011 Nov; 183(16):E1189-202. PubMed ID: 21989464
[TBL] [Abstract][Full Text] [Related]
34. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis.
Teng M; Lin L; Zhao YJ; Khoo AL; Davis BR; Yong QW; Yeo TC; Lim BP
Drugs Aging; 2015 Aug; 32(8):649-61. PubMed ID: 26245770
[TBL] [Abstract][Full Text] [Related]
35. Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Ponce OJ; Larrea-Mantilla L; Hemmingsen B; Serrano V; Rodriguez-Gutierrez R; Spencer-Bonilla G; Alvarez-Villalobos N; Benkhadra K; Haddad A; Gionfriddo MR; Prokop LJ; Brito JP; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1585-1594. PubMed ID: 30903687
[TBL] [Abstract][Full Text] [Related]
36. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
; Mangione CM; Barry MJ; Nicholson WK; Cabana M; Chelmow D; Coker TR; Davis EM; Donahue KE; Jaén CR; Kubik M; Li L; Ogedegbe G; Pbert L; Ruiz JM; Stevermer J; Wong JB
JAMA; 2022 Aug; 328(8):746-753. PubMed ID: 35997723
[TBL] [Abstract][Full Text] [Related]
37. Statin discontinuation in high-risk patients: a systematic review of the evidence.
Gomez Sandoval YH; Braganza MV; Daskalopoulou SS
Curr Pharm Des; 2011 Nov; 17(33):3669-89. PubMed ID: 22074437
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
